Monoclonal Antibodies Targeting Amyloid for Alzheimer Disease

<p>In this interview, dementia expert Gil D. Rabinovici, MD, discusses monoclonal antibodies that target beta-amyloid–-including a recent phase 3 trial of donanemab published in JAMA-–and reviews considerations for their use in patients with Alzheimer disease.<br /> <br /> <strong>Related Content:</strong></p> <ul> <li><a class="related-article" href= "https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2023.11703?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links" target="_blank" rel="noopener">Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease</a></li> <li><a class="related-article" href= "https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2023.13239?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links" target="_blank" rel="noopener">Donanemab in Early Symptomatic Alzheimer Disease</a></li> </ul>